KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of newly hired staff about the
phases of clinical drug research. Which statement by a
participant demonstrates the best understanding of a primary
purpose of Phase III clinical trials?
A. "The medication is tested for basic laboratory activity before
it is given to humans."
B. "The medication is evaluated in a large population to further
assess safety and effectiveness before widespread approval."
C. "The medication is tested only after it has been approved for
several years."
D. "The medication is evaluated exclusively in healthy
volunteers to determine the maximum tolerated dose."
Correct Answer: B
Rationale:
Phase III clinical trials involve large groups of participants and
are designed to confirm therapeutic effectiveness, identify less
common adverse effects, compare the drug with standard
therapies when appropriate, and provide additional safety
information before regulatory approval. Option A describes
preclinical research. Option C more closely reflects post-
marketing surveillance. Option D is more consistent with early
Phase I studies.
,Question 2
A patient asks why a newly prescribed medication required
years of testing before becoming available. Which response by
the nurse is most appropriate?
A. "Extensive testing helps determine whether the medication is
safe, effective, and manufactured with consistent quality."
B. "The testing period is primarily intended to increase the
medication's market value."
C. "The testing process guarantees that no adverse effects will
ever occur."
D. "Testing is required only to determine the lowest
manufacturing cost."
Correct Answer: A
Rationale:
Drug development is intended to establish reasonable evidence
of safety, effectiveness, appropriate dosing, and manufacturing
quality before widespread clinical use. Option B is incorrect
because commercial value is not the primary purpose of clinical
development. Option C is inaccurate because no medication is
completely free of risk. Option D does not reflect the purpose
of regulatory drug development.
Question 3
, A nurse is reviewing medication orders and notes that one
prescribed medication has a narrow therapeutic index. Which
nursing action is the highest priority?
A. Administer the medication without additional assessment
because the dose has already been prescribed.
B. Monitor prescribed laboratory values and assess carefully for
signs of toxicity or inadequate therapeutic effect.
C. Encourage the patient to double the dose if one dose is
missed.
D. Discontinue the medication whenever mild adverse effects
occur.
Correct Answer: B
Rationale:
Drugs with a narrow therapeutic index require careful
monitoring because small changes in drug concentration may
lead to toxicity or loss of therapeutic effect. Option A ignores
important safety considerations. Option C increases the risk of
toxicity. Option D is inappropriate because medications should
not be discontinued without appropriate clinical evaluation or
provider guidance.
Question 4
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of newly hired staff about the
phases of clinical drug research. Which statement by a
participant demonstrates the best understanding of a primary
purpose of Phase III clinical trials?
A. "The medication is tested for basic laboratory activity before
it is given to humans."
B. "The medication is evaluated in a large population to further
assess safety and effectiveness before widespread approval."
C. "The medication is tested only after it has been approved for
several years."
D. "The medication is evaluated exclusively in healthy
volunteers to determine the maximum tolerated dose."
Correct Answer: B
Rationale:
Phase III clinical trials involve large groups of participants and
are designed to confirm therapeutic effectiveness, identify less
common adverse effects, compare the drug with standard
therapies when appropriate, and provide additional safety
information before regulatory approval. Option A describes
preclinical research. Option C more closely reflects post-
marketing surveillance. Option D is more consistent with early
Phase I studies.
,Question 2
A patient asks why a newly prescribed medication required
years of testing before becoming available. Which response by
the nurse is most appropriate?
A. "Extensive testing helps determine whether the medication is
safe, effective, and manufactured with consistent quality."
B. "The testing period is primarily intended to increase the
medication's market value."
C. "The testing process guarantees that no adverse effects will
ever occur."
D. "Testing is required only to determine the lowest
manufacturing cost."
Correct Answer: A
Rationale:
Drug development is intended to establish reasonable evidence
of safety, effectiveness, appropriate dosing, and manufacturing
quality before widespread clinical use. Option B is incorrect
because commercial value is not the primary purpose of clinical
development. Option C is inaccurate because no medication is
completely free of risk. Option D does not reflect the purpose
of regulatory drug development.
Question 3
, A nurse is reviewing medication orders and notes that one
prescribed medication has a narrow therapeutic index. Which
nursing action is the highest priority?
A. Administer the medication without additional assessment
because the dose has already been prescribed.
B. Monitor prescribed laboratory values and assess carefully for
signs of toxicity or inadequate therapeutic effect.
C. Encourage the patient to double the dose if one dose is
missed.
D. Discontinue the medication whenever mild adverse effects
occur.
Correct Answer: B
Rationale:
Drugs with a narrow therapeutic index require careful
monitoring because small changes in drug concentration may
lead to toxicity or loss of therapeutic effect. Option A ignores
important safety considerations. Option C increases the risk of
toxicity. Option D is inappropriate because medications should
not be discontinued without appropriate clinical evaluation or
provider guidance.
Question 4
